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Evidence to Recommendations (EtR) Framework
 Decennial Td booster and tetanus prophylaxis in wound management
– Benefits and harms
• Focus on programmatic issues
– Values, preferences, acceptability and feasibility
– Resource use
– Work group interpretation
 Catch-up immunization schedule
Benefits and Harms
4Are there programmatic benefits to allowing either Td or 
Tdap to be used? 
 Provider ease and flexibility
– Challenging to determine patient history and receipt of previous Tdap 
– Cumbersome to stock both Td and Tdap vaccines
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– Challenging to determine patient history and receipt of previous Tdap 
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Work group interpretation: There are benefits to giving providers 
flexibility to use either Td or Tdap
6Are there benefits to repeat Tdap vaccination on pertussis 
prevention and control?
 Evidence that 2nd dose of Tdap is immunogenic
 Immunogenicity data on >2 doses of Tdap are lacking
 Uncertain duration of protection
– Evidence of short duration of protection in persons given acellular pertussis 
vaccines for their childhood series
– Lack of data on duration of protection among those primed with whole cell 
pertussis vaccines in childhood 
 Uncertain role in the prevention of transmission and herd immunity
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Work group interpretation: Insufficient evidence of benefit in pertussis 
control to recommend that Tdap replace Td for all decennial boosters
8Are there benefits to repeat Tdap for healthcare personnel?
 Reviewed by previous ACIP work group
 Pertussis transmission occurs in healthcare settings
 Insufficient data that healthcare personnel at increased risk for pertussis infection
 Lack of strong evidence that additional Tdap doses for healthcare personnel would 
be beneficial for pertussis control in healthcare settings 
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 Reviewed by previous ACIP work group
 Pertussis transmission occurs in healthcare settings
 Insufficient data that healthcare personnel at increased risk for pertussis infection
 Lack of strong evidence that additional Tdap doses for healthcare personnel would 
be beneficial for pertussis control in healthcare settings 
Work group interpretation: Insufficient evidence to have 
recommendations for healthcare personnel that are different than those 
for the general population
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Are there potential harms?
• Data lacking on safety of >2 Tdap doses
• Safety data of 2nd Tdap vaccination reviewed by previous Work Group with recent 
data presented at October 2018 ACIP meeting
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Are there potential harms?
• Data lacking on safety of >2 Tdap doses
• Safety data of 2nd Tdap vaccination reviewed by previous Work Group with recent 
data presented at October 2018 ACIP meeting
Work group interpretation: No substantive safety concerns
Work group interpretation: Benefits outweigh harms
Values, Preferences, Acceptability and 
Feasibility
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Do patients and providers value or have a preference for 
repeat Tdap vaccination? 
 No studies about values and acceptability for stakeholders
–
–
–
Target population: general adult population
Providers 
Immunization programs
 The proposed recommendation doesn’t require any additional vaccine doses
 Evidence indicating that repeat vaccination with Tdap is already a widespread
practice
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Provider dose ordering (public sector purchases): Adult Td 
and Tdap Doses, 2011-2017
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Tdap given more frequently than Td
1Jackson ML, et al. Safety of repeated doses of tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccine in adults and adolescents. 
Pharmacoepidemiol Drug Saf 2018 Aug;27(8):921-925. 
 Vaccine Safety Datalink1: 68,915 persons received Tdap and who received another 
Td-containing vaccine
• Tdap: 89%  
• Td: 11%
16
Tdap given more frequently than Td
1Jackson ML, et al. Safety of repeated doses of tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccine in adults and adolescents. 
Pharmacoepidemiol Drug Saf 2018 Aug;27(8):921-925. 2 Truven MarketScan databases, Outpatient Services Table, 2017. 
Commercial Insurance Claims:  
Persons aged 19 to 64 years, 20172
Tdap 716,638
Td 61,468
Tdap > Td claims: 
11.7x
 Vaccine Safety Datalink1: 68,915 persons received Tdap and who received another 
Td-containing vaccine
• Tdap: 89%  
• Td: 11%
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Is repeat Tdap vaccination acceptable and feasible?
 Evidence that the practice of giving Tdap in place of Td is already widespread 
despite: 
–
–
Not currently recommended by ACIP 
Off-label use of Tdap vaccines in clinical practice 
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Is repeat Tdap vaccination acceptable and feasible?
 Evidence that the practice of giving Tdap in place of Td is already widespread 
despite: 
–
–
Not currently recommended by ACIP 
Off-label use of Tdap vaccines in clinical practice
Work group interpretation: Allowing either Tdap or Td to be used would 
be acceptable and feasible for stakeholders, and may be preferred by 
providers
Resource Use
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Tdap is more expensive than Td 
1. Source: https://www.cdc.gov/vaccines/programs/vfc/awardees/vaccine-management/price-list/index.html, updated April 1, 2019
2. Indicates cost for 10 pack – 1 dose vial. 3. Vaccine cost includes $1.50 per dose Federal Excise Tax 4. Vaccine cost includes $2.25 per dose Federal Excise Tax 5. Source: Truven MarketScan
databases, Outpatient Services Table, DY 2016
CDC Vaccine price list1 CDC cost per dose2 Incremental cost of Tdap over Td
Td (TDVAX™)3 $13.96
Tdap (Boostrix®)4 $24.65 $10.68 
Tdap (Adacel®)4 $24.49 $10.53 
Commercial claims5 Median cost
Td (n=61,468) $27.38
Tdap (n=716,638) $44.07 $22.56
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Is allowing either Tdap or Td to be used a reasonable and 
efficient allocation of resources?
 Work Group reviewed economic impact analyses, including internal CDC analysis 
 Uncertainty on key parameters 
–
–
–
–
All economic analyses sensitive to pertussis incidence estimates 
Lack of reliable estimates of disease burden, particularly in adults
 Not accounted for:
Cost savings resulting from only carrying one vaccine
Repeat Tdap doses already given
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Is allowing either Tdap or Td to be used a reasonable and 
efficient allocation of resources?
 Work Group reviewed economic impact analyses, including internal CDC analysis 
 Uncertainty on key parameters 
–
–
–
–
All economic analyses sensitive to pertussis incidence estimates 
Lack of reliable estimates of disease burden, particularly in adults
 Not accounted for:
Cost savings resulting from only carrying one vaccine
Repeat Tdap doses already given
Work group interpretation: Economic impact analyses did not drive the decision-
making process for these programmatic questions
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Should any Td-containing vaccine (Tdap or Td) be allowed for use for the 
decennial Td booster and tetanus prophylaxis in the setting of wound 
management?
Criteria Work Group Interpretation
Benefits and Harms • Increased flexibility for providers
• May be some additional benefit for pertussis control
• Not enough evidence to recommend Tdap preferentially replace Td
• No substantive safety concerns
Benefits outweighs potential harms
Values, Acceptability and 
Feasibility
• Providers value flexibility
• Evidence of widespread use of Tdap instead of Td 
Valued by stakeholders; change is acceptable and feasible
Resource Use • Tdap more expensive than Td
• Economic analyses limited by uncertainty in key parameters
Economic impact not a major consideration
Should any Td-containing vaccine (Tdap or Td) be allowed 
for additional catch-up doses for those with incomplete 
or unknown vaccine history?
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Policy Options: Adolescent and adult series for those with 
incomplete or unknown vaccine history 
* Single dose of Tdap is preferred, followed by a dose of Td at least 4 weeks after Tdap and another dose of Td 6 to 12 months later. However, the single dose of 
Tdap can substitute for any of the Td doses in the 3-dose primary series. 
0 1 month 2 3 4 5 6 to 12 months
Td Td
1) No change
Tdap*
28
Policy Options: Adolescent and adult series for those with 
incomplete or unknown vaccine history 
* Single dose of Tdap is preferred, followed by a dose of Td at least 4 weeks after Tdap and another dose of Td 6 to 12 months later. However, the single dose of
Tdap can substitute for any of the Td doses in the 3-dose primary series. 
0 1 month 2 3 4 5 6 to 12 months
Td or Tdap
2) 1 dose Tdap, 2
doses Td OR Tdap
Tdap Td or Tdap
0 1 month 2 3 4 5 6 to 12 months
Td Td
1) No change
Tdap*
29
Policy Options: Adolescent and adult series for those with 
incomplete or unknown vaccine history 
* Single dose of Tdap is preferred, followed by a dose of Td at least 4 weeks after Tdap and another dose of Td 6 to 12 months later. However, the single dose of 
Tdap can substitute for any of the Td doses in the 3-dose primary series. 
0 1 month 2 3 4 5 6 to 12 months
Tdap Tdap
3) Three doses Tdap
Tdap
0 1 month 2 3 4 5 6 to 12 months
Td or Tdap
2) 1 dose Tdap, 2 
doses Td OR Tdap 
Tdap Td or Tdap
0 1 month 2 3 4 5 6 to 12 months
Td Td
1) No change
Tdap*
30
Policy Options: Adolescent and adult series for those with 
incomplete or unknown vaccine history 
* Single dose of Tdap is preferred, followed by a dose of Td at least 4 weeks after Tdap and another dose of Td 6 to 12 months later. However, the single dose of 
Tdap can substitute for any of the Td doses in the 3-dose primary series. 
0 1 month 2 3 4 5 6 to 12 months
Tdap Tdap
3) Three doses Tdap
Tdap
0 1 month 2 3 4 5 6 to 12 months
Td or Tdap
2) 1 dose Tdap, 2 
doses Td OR Tdap 
Tdap Td or Tdap
0 1 month 2 3 4 5 6 to 12 months
Td Td
1) No change
Tdap*
31
Should any Td-containing vaccine be allowed for additional catch-up 
doses in persons ≥7 years with incomplete or unknown vaccine history?
Criteria Work Group Interpretation
Benefits and Harms • Increased flexibility for providers
• May be some additional benefit for pertussis protection in previously 
unimmunized persons
• Not enough evidence to recommend Tdap preferentially replace Td
• No substantive safety concerns
Benefits outweighs potential harms
Values, Acceptability and 
Feasibility
• Providers value flexibility
• Gives providers more options if Td availability decreases
Valued by stakeholders; change is acceptable and feasible
Resource Use Economic impact not a major consideration for this policy question
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Catch-up immunization in pregnant women
 Current catch-up schedule same for pregnant women and general population
 Previously unimmunized women may require two doses of a tetanus toxoid-
containing vaccine to prevent obstetric and neonatal tetanus 
 Data are lacking on safety of multiple doses of Tdap during a single pregnancy
–
–
Registry data: Patients who received >1 dose during a single pregnancy 
No concerning safety signal for this or for women who receive closely-spaced 
Tdap vaccinations in different pregnancies
33
Catch-up immunization in pregnant women
 Current catch-up schedule same for pregnant women and general population
 Previously unimmunized women may require two doses of a tetanus toxoid-
containing vaccine to prevent obstetric and neonatal tetanus 
 Data are lacking on safety of multiple doses of Tdap during a single pregnancy
–
–
Registry data: Patients who received >1 dose during a single pregnancy 
No concerning safety signal for this or for women who receive closely-spaced 
Tdap vaccinations in different pregnancies
Work group interpretation: Recommendations for catch up immunization in 
pregnancy should continue to be similar to those for the general population
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Potential off-label recommendations
1 Current catch-up immunization recommendations: persons with incomplete or unknown vaccine history should receive a single dose of Tdap as one dose (preferably the first) of the three-
dose catch-up series. If additional doses are needed, Td is recommended. 2 Note on pregnancy: Both Tdap vaccines may be administered during pregnancy with the same intervals and 
restrictions (vaccine specific) as would apply to a non-pregnant individual. 3 Five or more years after a dose of DTaP or Td vaccine. 4 Please see Td package insert for indications and intervals 
for wound management
Licensed 
Tdap 
product
Current FDA indications, usage 
and administration
Possible off-label recommendations
Decennial Td booster 
(adults only)
Tetanus prophylaxis 
for wound 
management
Catch-up 
immunization 
series1,2
Adacel
(Sanofi 
Pasteur)
• Age: 10 through 64 years
• Routine booster3 with a 2nd
dose ≥8 years after first (any) 
Tdap dose
• Tetanus prophylaxis if ≥5 
years since last tetanus 
containing vaccine4
• Age ≥65 years
• Any dose beyond 
2nd Adacel dose
administered  ≥8 
years from first 
Tdap
• Age <10 or ≥65 
years
• Age 7 to 9 years
or ≥65 years
• >1 Tdap dose
Boostrix
(GSK) 
• Age: ≥10 years
• Single dose3
• Tetanus prophylaxis if no 
previous Tdap4
• Any dose if 
previously received 
Tdap
• Age <10 years
• Any dose if 
previously 
received Tdap
• Age 7 to 9 years
• >1 Tdap dose 
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Policy options for ACIP consideration
Policy question Work Group Interpretation
Either Tdap or Td can be used for the decennial Td 
booster We are in favor of the intervention
Either Tdap or Td can be used for tetanus prophylaxis in 
the setting of wound prophylaxis We are in favor of the intervention
Either Tdap or Td can be used for additional doses of the 
catch-up immunization schedule for persons ≥7 years We are in favor of the intervention
For more information, contact CDC
1-800-CDC-INFO (232-4636)
TTY:  1-888-232-6348    www.cdc.gov
The findings and conclusions in this report are those of the authors and do not necessarily represent the 
official position of the Centers for Disease Control and Prevention.
Questions?
